120
Participants
Start Date
January 12, 2023
Primary Completion Date
October 30, 2025
Study Completion Date
June 30, 2026
Q702
The study drug Q702 will be administered once daily by mouth on Days 1 through 7, Days 15 through 21 and Days 29 through 35 of every treatment cycle.
Pembrolizumab
Pembrolizumab will be administered using IV infusion on Day 1 of each 3-week treatment cycle
RECRUITING
Norton Cancer Institute, Louisville
RECRUITING
University of Southern California, Los Angeles
RECRUITING
CHA Bundang Medical Center, Seongnam-si
NOT_YET_RECRUITING
Asan Medical Center, Seoul
RECRUITING
Samsung Medical Center, Seoul
RECRUITING
Seoul National University Hospital, Seoul
RECRUITING
Severance Hospital, Seoul
Merck Sharp & Dohme LLC
INDUSTRY
Qurient Co., Ltd.
INDUSTRY